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ABSTRACT
Background Children with cancer are not at increased 
risk of severe SARS- CoV-2 infection; however, adults 
with haematological malignancies have increased risk 
of severe infections compared with non- haematological 
malignancies.
Methods We compared patients with haematological 
and non- haematological malignancies enrolled in the 
UK Paediatric Coronavirus Cancer Monitoring Project 
between 12 March 2020 and 16 February 2021. Children 
who received stem cell transplantation were excluded.
Results Only 2/62 patients with haematological 
malignancy had severe/critical infections, with an OR 
of 0.5 for patients with haematological compared with 
non- haematological malignancies.
Interpretation Children with haematological 
malignancies are at no greater risk of severe SARS- 
CoV-2 infection than those with non- haematological 
malignancies.
INTRODUCTION
Data previously published by our group have 
suggested that children with cancer are at no 
greater risk of severe infection with the coronavirus 
SARS- CoV-2 than other children.1 The UK Coro-
navirus Cancer Monitoring Project (UKCCMP) 
identified that adults with haematological malig-
nancies were more likely to have a severe/critical 
phenotype than patients with non- haematological 
malignancies.2
Given that approximately 40% of children with 
cancer are diagnosed with a haematological malig-
nancy, we performed a sub- analysis on our dataset 
to examine the severity of SARS- CoV-2 in this 
population.
METHODS
The UK Paediatric Coronavirus Cancer Monitoring 
Project (UKPCCMP) is a national database of chil-
dren less than 16 with an underlying diagnosis of 
malignancy attending hospital with evidence of 
COVID-19 infection.1 The database was designed 
as a public health surveillance registry to support 
rapid clinical decision- making, in accordance with 
the UK Policy Framework for Health and Social 
Care Research, the UK National Research Ethics 
Service and the UK Governance Arrangement 
for Research Ethic Committees. Research Ethics 
Committee approval was not required, as confirmed 
by the Health Research Authority. Reporting is 
undertaken by named professionals in all 20 UK 
paediatric oncology Principal Treatment Centres.
Patients were eligible for inclusion if they had 
a positive SARS- CoV-2 reverse transcriptase poly-
merase chain reaction (RT- PCR) test between 12 
March 2020 and 16 February 2021 and had an 
underlying diagnosis of any subtype of haemato-
logical malignancy including (but not limited to) 
all subtypes of leukaemia and lymphoma as well 
as myelodysplastic syndromes. Patients with other 
malignancies in the UKPCCMP cohort were used 
as a comparator. The cohort included both symp-
tomatic and asymptomatic patients screened prior 
to elective admission to hospital.
Patients who had undergone an allogeneic stem 
cell transplant were excluded from the database as 
their information is being reported separately by the 
European Society for Blood and Marrow Transplan-
tation (https://www. ebmt. org/ covid- 19- and- bmt).
An OR was estimated with 95% CIs to describe 
the risk of developing a severe/critical phenotype 
of COVID-19 in the haematological malignancy 
subgroup compared with the non- haematological 
malignancy subgroup. The latter group included 
patients with various CNS tumours, sarcomas, 
neuroblastomas and other, rarer tumours.
What is already known?
 ► Children with cancer are not at increased risk 
of severe infection with SARS- CoV-2 compared 
with the normal paediatric population. Adults 
with haematological malignancies are at 
increased risk of severe forms of SARS- CoV-2 
infection and death compared with adults with 
other malignancies.
What this study adds?
 ► Children with haematological malignancies are 
not at any increased risk of severe SARS- CoV-2 
infection than children with other malignancies. 
This is clearly different from adult patients and 
supports the continuation of routine care for 
these patients.
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RESULTS
Up to 16 February 2021, a total of 110 patients were registered; 
62 (56%) had a haematological malignancy. Table 1 shows the 
demographics and severity of COVID-19 infection in both 
groups.
In total, 2/62 patients (3.2%) with haematological malig-
nancies had severe/critical infections. Both patients had pre- B 
acute lymphoblastic leukaemia; one was receiving delayed inten-
sification and the other was receiving blinatumumab for non- 
remission after induction.
Also, 3/48 patients (6.3%) with non- haematological malignan-
cies had severe/critical infections. One had a hepatoblastoma on 
a background of chronic lung disease. One patient had an osteo-
sarcoma and was receiving postoperative chemotherapy. The 
final patient had a refractory stage 4 neuroblastoma.
Most patients with a positive SARS- CoV-2 test and haema-
tological malignancy had acute lymphoblastic leukaemia (ALL) 
(table 2).
In the UKPCCMP cohort, we did not identify any increased 
risk of severe/critical infection in children with haematological 
compared with non- haematological malignancies. The OR for 
severe/critical disease in patients with haematological compared 
with non- haematological disease was 0.50 (95% CI 0.08 to 
3.11). Also, 80% of patients in the haematological cohort were 
receiving their first line of chemotherapy compared with 83% of 
patients in the non- haematological cohort.
DISCUSSION
In this updated analysis on our initial review of the severity of 
COVID-19 in children with cancer in the UK, we focus specif-
ically on comparing patients with haematological and non- 
haematological malignancies.
Since the beginning of the pandemic, a number of groups 
including our own have published data on the severity of 
COVID-19 in children with cancer and on the severity of 
COVID-19 in patients with different haematological malig-
nancies.3–5 This cohort specifically compares the severity of 
infection between paediatric patients with haematological and 
non- haematological malignancies.
The adult UKCCMP reported that patients with haematolog-
ical malignancies have a significantly higher case- fatality rate 
than patients with non- haematological malignancies (OR 2.25, 
95% CI 1.13 to 4.57).2 Similar findings have been reported by 
other groups.6 7
In our haematological malignancy cohort, there were no 
deaths related to COVID-19 and only two patients required 
intensive care support. Also, 31% of patients were asymptom-
atic and were identified either through targeted screening prior 
to a general anaesthetic or were admitted for another reason 
and incidentally found to be SARS- CoV-2 positive. In the non- 
haematological cohort, 36% were asymptomatic. Thus, there 
was no evidence of a higher rate of asymptomatic cases in the 
haematological cohort despite a higher rate of general anaes-
thetics, suggesting that the estimated OR of 0.50 for developing 
severe or critical disease was not due to higher rates of detec-
tion by asymptomatic screening. In the adult UKCCMP cohort, 
119/227 patients with haematological malignancies (52.4%) had 
severe or critical infections. They had an increased risk of severe/
critical infections compared with those with non- haematological 
malignancies (OR 1.55, 95% CI 1.16 to 2.09).2
Given the OR for severe/critical disease in patients with 
haematological malignancies compared with non- haematological 
malignancies was 0.5, there is a possibility that the risk of severe/
critical infection may actually be higher in children with non- 
haematological malignancies, but the small numbers make it 
difficult to draw any conclusion.
In the UKPCCMP cohort, 63.6% of patients had a mild 
infection that either did not require admission to hospital or 
had a short stay with no need for additional therapy such as 
supplemental oxygen. This figure remains consistent with our 
previously reported cohort in which 63% of patients had a mild 
infection, highlighting the stability of the data over time.
Approximately 40% of children diagnosed with cancer across 
the UK have a haematological malignancy,8 but 54% of patients 
in the UKPCCMP paediatric cohort had a haematological malig-
nancy, 76% of whom had ALL. Treatment for ALL lasts 2–3 
years, compared with 6 months of treatment for most other 
malignancies, resulting in an on- treatment prevalence for ALL 
that is higher than its incidence. This may partly explain the 
high proportion of patients with ALL in our cohort. Others have 
proposed that the relatively greater and more prolonged lymph-
openia of patients with haematological malignancies may render 
them more susceptible to contracting viral infections in general 
including SARS- CoV-2.6








Sex   
  Male 35 (56%) 34 (71%)
  Female 27 (44%) 14 (29%)
Median age 
(range)
  7 years, 7 months 
(4 months to 15 
years, 9 months)
3 years, 10 months 
(1 month to 15 years, 
9 months)
Ethnicity   
  White 37 (59.7%) 23 (47.9%)
  Black 3 (4.8%) 4 (8.3%)
  Asian 13 (21%) 8 (16.7%)
  Other 3 (4.8%) 4 (8.3%)




  Asymptomatic 19 (30.6%) 17 (35.4%)
  Mild 39 (62.9%) 27 (56.2%)
  Moderate 2 (3.2%) 1 (2.1%)
  Severe 1 (1.6%) 1 (2.1%)
  Critical 1 (1.6%) 2 (4.2%)
UKPCCMP, UK Paediatric Coronavirus Cancer Monitoring Project.
Table 2 Underlying diagnosis of patients with haematological 





Acute lymphoblastic leukaemia 48 (77.4)
Acute myeloid leukaemia 8 (12.9)
Acute leukaemia, not otherwise specified 1 (1.6)
Lymphoma 5 (8)
Hodgkin’s lymphoma 3 (4.8)
Burkitt’s lymphoma 2 (3.2)
UKPCCMP, UK Paediatric Coronavirus Cancer Monitoring Project.
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The major strength of our study is that all principal treatment 
centres caring for children with cancer in the UK were enrolled. 
While some patients with positive SARS- CoV-2 PCR results may 
not have been registered on the UKPCCMP database, rigorous 
and repeated follow- up with participating centres has ensured 
near complete capture of childhood cancers attending hospital 
in the reported timeframe.
The major limitation of our study is the relatively small 
numbers of patients involved. However, the results shown here 
are remarkably similar to the data we published for all children 
with cancer last year. A specific limitation with regard to our 
haematological cohort is our elective omission of patients who 
had undergone an allogeneic stem cell transplant as they were 
being captured by another registry study. This decision does 
limit our ability to generalise our findings to all patients with 
haematological malignancies, but the conclusion that paediatric 
patients with cancer are at no greater risk of severe COVID-19 
infection remains relevant for those who have not had an allo-
geneic transplant. Furthermore, less than 1% of patients with 
haematological malignancies in the adult UKCCMP cohort had 
allogeneic stem cell transplants (personal communication). This 
therefore means that, although we excluded patients who were 
post- allogeneic transplant from our dataset, the two sets are 
largely comparable.
CONCLUSION
Our data suggest that children with haematological malignan-
cies who have not had an allogeneic stem cell transplant are not 
at greater risk of severe infection with SARS- CoV-2 than other 
children with cancer. This supports the recommendations that 
children with haematological malignancies need not be consid-
ered extremely vulnerable and should continue with standard of 
care therapy without modification attendant on the SARS- CoV-2 
pandemic.
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